Drug Test Anal August 27, 2026
Synthesis and Analytical Characterization of 1-(1,2-Dimethylcyclobutane-1-Carbonyl)-Lysergic Acid Diethylamide (1D-LSD) and Differentiation From 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD).
Neurosci Conscious August 20, 2026
Low-dose lysergic acid diethylamide alters subjective visual perception but not visual contrast surround suppression.
bioRxiv August 18, 2026 preprint
Tuning in together: LSD enhances inter-brain synchrony and felt connectedness in romantic couples
Med (New York, N.Y.) August 14, 2026 Felix Müller, Anna M Becker, Christopher Böhlke et al.
In Basel, only a few hundred meters from where LSD was first synthesized, we tested LSD-assisted therapy for major depression in a randomized trial comparing two high doses with two low doses, each paired with supportive psychotherapy. This Backstory reflects on treating patients, long dosing days, and what remains uncertain.
Exp Clin Psychopharmacol August 10, 2026
The impact of fluoxetine on the aversive effects of lysergic acid diethylamide.
Anal Bioanal Chem July 28, 2026
High-sensitivity immunochromatographic assay based on time-resolved fluorescence microspheres for the simultaneous detection of mescaline and LSD in hair.
medRxiv July 19, 2026 Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al.
Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10-25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be separated from its hallucinogenic activity remains unresolved. To address this gap, we conducted a Phase...
July 10, 2026 Lohani Noor
A resurgent therapeutic frontier, the contemporary renaissance in psychedelic science has accelerated investigation of classic serotonergic psychedelics (psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), mescaline), empathogenic entactogenic agents (3,4-methylenedioxymethamphetamine (MDMA)), and glutamatergic dissociatives (ketamine) as adjuncts to psychotherapy. While...
Journal of Science Policy & Governance July 2, 2026 Matthew A. Boehm, Oriana Mayorga
There is growing interest in psychedelic compounds such as psilocybin, 3,4-metheylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) given emerging research on potential uses as treatments for a variety of health conditions. The United States Food and Drug Administration (FDA) has granted multiple “Breakthrough Therapy” designations to various...
Archives of Toxicology July 1, 2026 Kamil Jurowski, Alicja Krośniak, Damian Kobylarz et al.
Lysergamide analogs such as ALD-52, 1P-LSD, 1B-LSD, 1 V-LSD, and 1cP-LSD have emerged as new psychoactive substances (NPS) with hallucinogenic potential, yet their toxicological profiles remain largely unexplored. In this study, a comprehensive in silico assessment was conducted using multiple platforms (e.g., ADMETlab 3.0, Percepta, STopTox, ProTox 3.0, VEGA, TEST 5.1.2) to predict critical...
Pharmacology & Therapeutics May 1, 2019 Matthew W Johnson, Peter S. Hendricks, Frederick S. Barrett et al. 520 citations
The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been administered as sacraments since ancient times. They were of prominent interest...
Scientific Reports April 19, 2017 Michael Schartner, Robin Carhart-Harris, Adam B. Barrett et al. 450 citations
Abstract What is the level of consciousness of the psychedelic state? Empirically, measures of neural signal diversity such as entropy and Lempel-Ziv (LZ) complexity score higher for wakeful rest than for states with lower conscious level like propofol-induced anesthesia. Here we compute these measures for spontaneous magnetoencephalographic (MEG) signals from humans during altered states of...
Cell January 26, 2017 Daniel Wacker, Sheng Wang, John D. Mccorvy et al. 466 citations
SUMMARY The prototypical hallucinogen LSD acts via serotonin receptors, and here we describe the crystal structure of LSD in complex with the human serotonin receptor 5-HT2B. The complex reveals conformational rearrangements to accommodate LSD, providing a structural explanation for the conformational selectivity of LSD’s key diethylamide moiety. LSD dissociates exceptionally slowly from both...
Curr Biol April 13, 2016 Enzo Tagliazucchi, Leor Roseman, Mendel Kaelen et al. 531 citations
Lysergic acid diethylamide (LSD) is a non-selective serotonin-receptor agonist that was first synthesized in 1938 and identified as (potently) psychoactive in 1943. Psychedelics have been used by indigenous cultures for millennia [1]; however, because of LSD's unique potency and the timing of its discovery (coinciding with a period of major discovery in psychopharmacology), it is generally...
Proc Natl Acad Sci U S A April 11, 2016 Robin Carhart-Harris, Suresh Muthukumaraswamy, Leor Roseman et al. 887 citations
Lysergic acid diethylamide (LSD) is the prototypical psychedelic drug, but its effects on the human brain have never been studied before with modern neuroimaging. Here, three complementary neuroimaging techniques: arterial spin labeling (ASL), blood oxygen level-dependent (BOLD) measures, and magnetoencephalography (MEG), implemented during resting state conditions, revealed marked changes in...
Biological Psychiatry November 29, 2014 Yasmin Schmid, Florian Enzler, Peter Gasser et al. 425 citations
BackgroundAfter no research in humans for >40 years, there is renewed interest in using lysergic acid diethylamide (LSD) in clinical psychiatric research and practice. There are no modern studies on the subjective and autonomic effects of LSD, and its endocrine effects are unknown. In animals, LSD disrupts prepulse inhibition (PPI) of the acoustic startle response, and patients with...
Journal of Psychopharmacology November 11, 2014 Peter Gasser, Katharina Kirchner, Torsten Passie 458 citations
Objective: A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with life-threatening diseases. Participants of this study were included in a prospective follow-up. Method: 12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A...
The Journal of Nervous and Mental Disease March 4, 2014 Peter Gasser, Dominique Holstein, Yvonne Michel et al. 752 citations
A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received...
Science March 21, 2013 Daniel Wacker, Chong Wang, Vsevolod Katritch et al. 689 citations
Dissecting Serotonin Receptors Serotonin receptors are the targets for many widely used drugs prescribed to treat ailments from depression to obesity and migraine headaches (see the Perspective by Palczewski and Kiser ). C. Wang et al. (p. 610 , published online 21 March) and Wacker et al. (p. 615 , published online 21 March) describe crystal structures of two members of the serotonin family of...
Journal of Psychopharmacology March 8, 2012 Teri Suzanne Krebs, Pål-ørjan Johansen 580 citations
Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse...
CNS Neuroscience & Therapeutics November 11, 2008 Torsten Passie, John H. Halpern, Dirk O. Stichtenoth et al. 459 citations
Lysergic acid diethylamide (LSD) was synthesized in 1938 and its psychoactive effects discovered in 1943. It was used during the 1950s and 1960s as an experimental drug in psychiatric research for producing so‐called “experimental psychosis” by altering neurotransmitter system and in psychotherapeutic procedures (“psycholytic” and “psychedelic” therapy). From the mid 1960s, it became an illegal...
Trends in Pharmacological Sciences August 1, 2008 Mark A. Geyer, Franz X. Vollenweider 435 citations
The history of serotonin research is closely related to the study of hallucinogenic drugs that function as agonists at serotonin-2A receptors. The fundamental idea that psychotic states seen in psychiatric disorders such as schizophrenia might be attributable, in part, to abnormalities in serotonergic systems began with the almost simultaneous discovery of lysergic acid diethylamide (LSD),...
Molecular Pharmacology December 1, 2001 James R. Bunzow, Mark S. Sonders, Seksiri Arttamangkul et al. 644 citations
The trace amine para-tyramine is structurally and functionally related to the amphetamines and the biogenic amine neurotransmitters. It is currently thought that the biological activities elicited by trace amines such as p-tyramine and the psychostimulant amphetamines are manifestations of their ability to inhibit the clearance of extracellular transmitter and/or stimulate the efflux of...
Archives of General Psychiatry February 1, 1994 Ruck J. Strassman 454 citations
BACKGROUND: Validation of animal models of hallucinogenic drugs' subjective effects requires human data. Previous human studies used varied groups of subjects and assessment methods. Rating scales for hallucinogen effects emphasized psychodynamic principles or the drugs' dysphoric properties. We describe the subjective effects of graded doses of N,N-dimethyltryptamine (DMT), an endogenous...